Health Condition 1: L80- Vitiligo
Conditions
Interventions
Intervention1: Oral Tofacitinib: Patients will be randomized into two groups
one group will receive Oral Tofacitinib in the dose of 5mg twice daily for 120 days and the other group will receive Oral methylprednisolone minipulse steroid treatment in standard doses of 0.5mg/Kg b
one group will receive Oral methylprednisolone minipulse steroid treatment in standard doses of
0.5mg/Kg body weight (maximum of 32mg on two consecutive days every week) for 120 days and the other gr
Sponsors
Dr Imran Majid
Dr Sehar Imran
Eligibility
Inclusion criteria
Inclusion criteria: Patients with a confirmed diagnosis of vitiligo, Washout period for Systemic medication for vitiligo for atleast 1 month before enrolment, Written informed consent signed by the patient or legally acceptable representative(s) in line with applicable regulation of country, Planned treatment in line with the Summary of Product Characteristics
Exclusion criteria
Exclusion criteria: any contraindication to any of the oral medications, women of childbearing age, pregnancy, lactation, any family history of diabetes in parents/siblings, Confirmed case of Latent Tuberculosis on investigation, unwillingness to conform to study protocol
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The study is being planned to conduct a comparative assessment to explore the safety & efficacy of Oral Tofacitinib versus methylprednisolone oral minpulse therapy in vitiligo patients to develop/upgrade the literatureTimepoint: 1 year | — |
Secondary
| Measure | Time frame |
|---|---|
| To obtain safety information in terms of adverse events on the use Oral Tofacitinib versus methylprednisolone oral minpulse therapy in vitiligo patients.Timepoint: 1 year | — |
Countries
India
Contacts
Public ContactDr Imran Majid
Cutis Institute of Dermatology
Outcome results
None listed